A synthetic analogue of endogenous GHRH with a trans-3-hexenoic acid modification for enhanced half-life. FDA-approved for lipodystrophy research. Unlike direct GH peptides, Tesamorelin stimulates the pituitary to release GH in a pulsatile, physiologic pattern — preserving the natural feedback axis.
Tesamorelin has been extensively studied across multiple research domains. Below are the primary areas of published research.
Browse on PubMed →